Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
10512 studies found for:    NCI
Show Display Options
Download search resultsDownload the search results for:
NCI (10512 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Completed Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: aldesleukin;   Biological: fowlpox virus vaccine vector;   Biological: gp100 antigen
2 Completed Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
Conditions: Accelerated Phase of Disease;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia;   Previously Treated Myelodysplastic Syndrome;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Disease;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome
Interventions: Drug: Belinostat;   Drug: Azacitidine;   Other: Laboratory Biomarker Analysis
3 Active, not recruiting Vorinostat, Paclitaxel, and Bevacizumab in Treating Patients With Metastatic Breast Cancer and/or Breast Cancer That Has Recurred in the Chest Wall and Cannot be Removed by Surgery
Conditions: Male Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: vorinostat;   Drug: paclitaxel;   Biological: bevacizumab;   Other: laboratory biomarker analysis
4 Active, not recruiting
Has Results
Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: lenalidomide;   Drug: dexamethasone;   Drug: thalidomide;   Other: laboratory biomarker analysis
5 Active, not recruiting Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases
Conditions: Bone Metastases;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Intervention: Radiation: fluorine F 18 sodium fluoride
6 Recruiting CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma
Conditions: Carcinoma of Unknown Primary Origin;   Iris Melanoma;   Medium/Large Size Posterior Uveal Melanoma;   Mucosal Melanoma;   Ocular Melanoma With Extraocular Extension;   Small Size Posterior Uveal Melanoma;   Stage IIB Skin Melanoma;   Stage IIB Uveal Melanoma;   Stage IIC Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIA Uveal Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Skin Melanoma;   Stage IIIC Uveal Melanoma;   Stage IV Skin Melanoma;   Stage IV Uveal Melanoma
Interventions: Biological: recombinant flt3 ligand;   Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401;   Biological: Neoantigen-based Melanoma-Poly-ICLC Vaccine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
7 Completed Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye
Conditions: Extraocular Extension Melanoma;   Recurrent Intraocular Melanoma
Interventions: Drug: gp100 antigen;   Drug: interleukin-2;   Drug: MART-1 antigen;   Drug: Montanide ISA-51
8 Completed Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Promyelocytic Leukemia (M3);   Recurrent Adult Acute Myeloid Leukemia
Intervention: Drug: romidepsin
9 Active, not recruiting First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: trastuzumab;   Drug: paclitaxel;   Drug: carboplatin;   Other: placebo;   Biological: bevacizumab;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
10 Terminated Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma
Conditions: Stage III Melanoma;   Stage IV Melanoma
Interventions: Drug: cilengitide;   Other: pharmacological study;   Other: laboratory biomarker analysis
11 Recruiting Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Serous Surface Papillary Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: WEE1 Inhibitor MK-1775;   Drug: Gemcitabine Hydrochloride;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
12 Completed Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: filgrastim;   Biological: recombinant interleukin-12;   Drug: etoposide;   Drug: ifosfamide
13 Active, not recruiting Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
Conditions: Acral Lentiginous Malignant Melanoma;   Lentigo Maligna Malignant Melanoma;   Nodular Malignant Melanoma;   Recurrent Melanoma;   Solar Radiation-related Skin Melanoma;   Stage IV Melanoma;   Superficial Spreading Malignant Melanoma
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis
14 Recruiting Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors
Conditions: Ductal Breast Carcinoma In Situ;   Lobular Breast Carcinoma In Situ;   Paget Disease of the Breast;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Docosahexaenoic Acid;   Other: Placebo;   Other: Laboratory Biomarker Analysis
15 Completed Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Condition: Head and Neck Cancer
Intervention: Drug: thalidomide
16 Completed Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma
Condition: AIDS-related Kaposi Sarcoma
Interventions: Drug: paclitaxel;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
17 Completed Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
Conditions: Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Bladder Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Stage III Bladder Cancer;   Stage III Urethral Cancer;   Stage IV Bladder Cancer;   Stage IV Urethral Cancer;   Transitional Cell Carcinoma of the Bladder;   Ureter Cancer
Intervention: Drug: bortezomib
18 Completed A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer
Condition: Recurrent Non-small Cell Lung Cancer
Interventions: Drug: triapine;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis
19 Completed
Has Results
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: cediranib maleate;   Other: laboratory biomarker analysis
20 Completed LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma
Conditions: Leukemia;   Lymphoma
Intervention: Biological: LMB-2 immunotoxin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years